Lourdes Anta

Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies

Lourdes Anta, Josep M. Llibre, Eva Poveda et al. · AIDS · 2012 · 59 citations · Full text

Phase I, open-label, randomized, parallel study to evaluate the pharmacokinetics, safety, and tolerability of one intramuscular injection of risperidone ISM at different dose strengths in patients with schizophrenia or schizoaffective disorder (PRISMA-1)

Jordi Llaudó, Lourdes Anta, I. Ayani et al. · International Clinical Psychopharmacology · 2016 · 24 citations

Drug Safety, Therapeutic Drug Monitoring, Dose Administration +12

HIV-1 genotypic drug resistance interpretation rules - 2009 Spanish guidelines.

Carmen de Mendoza, Lourdes Anta, Féderico García et al. · PubMed · 2009 · 22 citations

Pharmacotherapy, Antiviral Drug, Harm Reduction +18

Long-term efficacy and safety of once-monthly Risperidone ISM® in the treatment of schizophrenia: Results from a 12-month open-label extension study

Yuriy Filts, Robert E. Litman, Javier Martínez et al. · Schizophrenia Research · 2021 · 19 citations · Full text

Rilpivirine: a next-generation non-nucleoside analogue for the treatment of HIV infection

José Vicente Fernández-Montero, Eugenia Vispo, Lourdes Anta et al. · Expert Opinion on Pharmacotherapy · 2012 · 17 citations